On a day when markets may have been moving at half-speed, in sympathy with their American brethren, about to embark on a long Thanksgiving, Toronto-base Theralase Technologies Inc. (TSX-Venture:TLT) climbing the charts Wednesday on word of new publications by its researchers.
Theralese is a clinical-stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce several scientific recognitions.
The recognition from three scientific institutes emphasizes the strong science-based technology that the Company possesses, verifying that Theralase's Ruthenium-based PDCs are leading the pack in terms of performance of Photo Dynamic Therapy metal based PDCs to become the next viable option for treating various cancers, suggesting a major change in the way various cancers are treated in the future.
TLT was also honoured to be awarded the Best Poster at the American Urological Association Annual Meeting in Chicago, which was published on AUA news magazine in its October issue.
Said Chief Scientific Officer Arkady Mandel, "It is exciting to witness Theralase's scientific and clinical research being widely recognized by prominent scientific and clinical organizations, internationally. These publications support the robustness of Theralase's technology and the clear advantages of using TLD-1433 in the treatment of (bladder cancer)."
TLT shares gained 1.5 cents, or 6.4%, to 25 cents, on volume of 391,000